ProBNP

BNPP

PBNP
nt-pro BNP
PROBNP
 

1.0 mL plasma collected in a PST (LiHeparin tube)

0.5 mL

SST (Gold) tube
Red top tube
EDTA (Lavendar)
Tiger top tube

Room Temperature: 3 days at 20 - 25°C Refrigerated: 6 days at 2 - 8°C Frozen: 24 month at ­-20°C. Freeze only once.

 Grossly hemolyzed.

Sun-Sat

Same day

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

Serum concentrations of natriuretic peptides may be elevated in patients with acute myocardial infarction, patients that are candidates for renal dialysis, and patients that have undergone renal dialysis.

< 450 pg/mL for adults < 50 years old
< 900 pg/mL for adults 50 - 75 years old
< 1800 pg/mL for adults > 75 years old

This assay is used as an aid in the diagnosis of individuals suspected of having congestive heart failure. The test is further indicated for the risk stratification of patients with acute coronary syndrome and congestive heart failure. The test may also serve as an aid in the assessment of increased risk of cardiovascular events and mortality in patients at risk for heart failure who have stable coronary artery disease.
Left ventricular dysfunction can occur as a part of coronary heart disease, arterial hypertension, valvular disease, and primary myocardial disease. If the left ventricular dysfunction remains untreated and is progressive, the potential for mortality is high, e.g. due to sudden cardiac death. Chronic cardiac insufficiency is a clinical syndrome caused by impairment of the cardiac pumping function. The significance of natriuretic peptides in the control of cardiovascular system function has been demonstrated. Studies reveal that natriuretic peptides can be used for diagnostic clinical problems associated with left ventricular dysfunction. The following natriuretic peptides have been described: atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). In subjects with left ventricular dysfunction, serum and plasma concentrations of BNP increase, as do the concentrations of the biologically inactive prohormone, proBNP.
ProBNP, comprising 108 amino acids, is secreted mainly by the ventricle and, in this process, is cleaved into physiologically active BNP (77-108) and the N-terminal fragment NT-proBNP (1-76). Studies indicate that NT-proBNP can be used in diagnostic and prognostic applications. Three studies involving patients with stable coronary artery disease have shown that elevated levels of NT-proBNP lead to a greater risk of future adverse events. The test is also useful in assigning symptoms to cardiac or non-cardiac causes, and helps to identify subjects with left ventricular dysfunction. The European Society of Cardiology Task Force for the Diagnosis and Treatment of Chronic Heart Failure recommend in their guidelines that natriuretic peptides including NT-proBNP “may be most useful clinically as a rule out test due to consistent and very high negative predictive values”.